Difficulty in predicting survival in metastatic renal cancer

The Lancet Oncology

Volumn 13, Issue 9, 2012, Pages 859-860

  Powles, Tom ^a   Hutson, Thomas E ^b,c  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b Texas Oncology   (United States)

^c BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SORAFENIB; SUNITINIB; TEMSIROLIMUS;

CANCER PROGNOSIS; CANCER SURVIVAL; COHORT ANALYSIS; HUMAN; IMAGE ANALYSIS; KIDNEY CARCINOMA; LETTER; METASTASIS; PREDICTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; TREATMENT OUTCOME;

CARCINOMA, RENAL CELL; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR;

EID: 84865571941     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(12)70318-2     Document Type: Letter

References (11)

1. Powles T, Chowdhury S, Jones R, et al. Sunitinib and other targeted therapies for renal cell carcinoma. Br J Cancer 2011, 104:741-745.
2. Motzer RJ, Hutson TE, Tomczak P, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009, 27:3584-3590.
3. Mickisch GH, Garin A, van Poppel H, de Prijck L, Sylvester R Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 2001, 358:966-970. European Organisation for Research and Treatment of Cancer (EORTC) Genitourinary Group.
4. Heng DY, Xie W, Regan MM, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol 2009, 27:5794-5799.
5. Lorch A, Beyer J, Bascoul-Mollevi C, et al. Prognostic factors in patients with metastatic germ cell tumors who experienced treatment failure with cisplatin-based first-line chemotherapy. J Clin Oncol 2010, 28:4906-4911.
6. Kontovinis LF, Papazisis KT, Touplikioti P, et al. Sunitinib treatment for patients with clear-cell metastatic renal cell carcinoma: clinical outcomes and plasma angiogenesis markers. BMC Cancer 2009, 9:82.
7. Kayani I, Avril N, Bomanji J, et al. Sequential FDG-PET/CT as a biomarker of response to Sunitinib in metastatic clear cell renal cancer. Clin Cancer Res 2011, 17:6021-6028.
8. Pfizer provides topline results from phase 3 study of Torisel as second-line treatment in advanced renal cell carcinoma (RCC) Pfizer, (accessed May 15, 2012). http://www.pfizer.com/news/press_releases/pfizer_press_release.jsp?guid=20120515006852en&source=RSS_2011&page=2.
9. Axitinib approval document FDA, (accessed June 6, 2012). http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/oncologicdrugsadvisorycommittee/ucm282290.pdf.
10. Stewart D, O'Mahony F, Eory L, et al. Proteomic analysis of pre- and post-sunitinib treated renal cancer tissue to assess tumor heterogeneity and differential protein expression. Proc Am Soc Clin Oncol 2012, 30(suppl 5). abstr 388.
11. Harshman LC, Xie W, Bjarnason GA, et al. Conditional survival of patients with metastatic renal-cell carcinoma treated with VEGF-targeted therapy: a population-based study. Lancet Oncol 2012, published online Aug 7. http://dx.doi.org/10.1016/S1470-2045(12)70285-1.